Novartis stock declined following another clinical trial failure, dealing a blow to the drugmaker's efforts to revive its growth prospects. The setback involves a neuromuscular treatment that failed to meet its primary endpoint in a late-stage study. This latest disappointment adds to a string of pipeline challenges for the Swiss pharmaceutical giant as it attempts to offset patent expirations and stimulate revenue growth.

Investors reacted negatively to the news, sending shares lower in early trading. The failed treatment was viewed as a key component of Novartis's strategy to strengthen its neuroscience portfolio. Management has not yet detailed specific next steps for the program but emphasized its commitment to the therapeutic area.

Analysts suggest the failure increases pressure on the company's remaining pipeline assets to deliver successful readouts. The development underscores the inherent risks in drug development, particularly in complex neurological indications where success rates remain low.